Swe­den's Cal­lid­i­tas seeks $75M IPO haul to bring its oral steroid to pa­tients with an or­phan kid­ney dis­ease

As biotech af­ter biotech elic­its en­thu­si­as­tic in­vestor sup­port for this cor­ner of the IPO mar­ket, a Swedish play­er is join­ing the Nas­daq line to fund the last leg of its clin­i­cal jour­ney.

Cal­lid­i­tas Ther­a­peu­tics is eye­ing a $75 mil­lion raise, a mod­est sum com­pared to some of the big­ger pub­lic de­buts we’ve seen in re­cent days — but they could well up­size the of­fer­ing like oth­er small, ob­scure com­pa­nies be­fore them have done.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER